NCT04567810View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions

Covid19

Interventions

DRUG

anti-SARS-CoV-2 IgY

anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

DRUG

Placebo

Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Trial Locations (1)

6009

Linear Clinical Research - Harry Perkins Research Institute, Nedlands

All Listed Sponsors

lead

Stanford University

OTHER

NCT04567810 - Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19) | Biotech Hunter | Biotech Hunter